Any current/future capex/capital investment/strategic investment?

Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17). Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12). Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6). Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6). Manufacturing footprint in the U.S. is being constantly

Future growth expectations in sales/revenue/volumes?

Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. U.S. Innovative Medicine sales have surpassed generics for the first time, indicating growth focus. India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Specialty products like ILUMYA expected to continue prescription growth due to expanding markets. Targeted treatments like Leqselvi market expected to grow with increasing prescriber confidence and payer coverage. GLP-1 market described as very exciting wit

Future growth expectations in earnings/operating earnings/profits/EPS?

Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits. Specialty product launches (Leqselvi, Unloxcyt) will increase related sales and marketing expenses into H2 FY26 and beyond, supporting growth. U.S. Innovative Medicines sales are surpassing generics, indicating growth emphasis on higher-value specialty medicines. Continued growth expected for ILUMYA and specialty biologics in the U.S. and global markets. The company remains competitive in emerging GLP-1 market, aiming to participate at first opportunity once pate

IN US

Sale is live|00:00:00left today

Sun Pharmaceutical Industries LtdQ3 FY25Pharmaceuticals & Biotechnology

Sun Pharmaceutical Industries Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,874P/E: 37.1Market Cap: ₹4.5L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue.
→U.S. Innovative Medicine sales have surpassed generics for the first time, indicating growth focus.
→India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches.
→Specialty products like ILUMYA expected to continue prescription growth due to expanding markets.
→Targeted treatments like Leqselvi market expected to grow with increasing prescriber confidence and payer coverage.
→GLP-1 market described as very exciting with expected growth; Sun Pharma aims to participate actively.
→New product launches (e.g., Unloxcyt) supported by $100 million incremental spend, with anticipation of increased expenses into H2 FY26.
→Overall, the company anticipates continued growth in innovative medicines and specialty segments, with generics business being stable but lower growth.

Margin guidance

Category 3

→Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
→Specialty product launches (Leqselvi, Unloxcyt) will increase related sales and marketing expenses into H2 FY26 and beyond, supporting growth.
→U.S. Innovative Medicines sales are surpassing generics, indicating growth emphasis on higher-value specialty medicines.
→Continued growth expected for ILUMYA and specialty biologics in the U.S. and global markets.
→The company remains competitive in emerging GLP-1 market, aiming to participate at first opportunity once patents expire; long-term growth anticipated here.
→R&D spend expected at lower end of 6%-8% guidance, possibly improving pipeline but controlling costs.
→Cash flow expected to normalize by year-end after working capital and acquisition-related impacts.
→Overall, cautious optimism with growth driven by innovative medicines and specialty portfolio, supported by disciplined cost and investment management.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

- There is no explicit mention of any new fundraising through debt or equity in the transcript. - Short-term borrowings have increased in the quarter due to the recent acquisition. - Jayashree Satagopan clarified that this short-term borrowing taken for the acquisition is expected to be reduced and normalized over the coming quarters. - The company is managing cash flows with some increase in working capital and settlements related to acquisitions, but no indication of new fundraises. - The firm maintains a healthy cash position and is open to considering investments such as U.S.-based manufacturing but no direct mention of raising funds for this purpose. **Summary:** Current short-term borrowings reflect acquisition financing; no plans or announcements for new debt or equity fundraising were disclosed.

Order book

The provided transcript from Sun Pharma's Q2 FY26 earnings call does not explicitly mention details about the current or expected order book or pending orders. Hence, there is no direct information available regarding: - Current order book status - Expected order book updates - Pending orders or backlog levels The call primarily covers financial results, business segments, acquisitions, R&D, tax rates, and product launch updates without specific reference to order book or pending orders data.

Capex plans

Yes

→Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17).
→Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12).
→Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6).
→Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6).
→Manufacturing footprint in the U.S. is being constantly assessed with openness to increase U.S.-based manufacturing given policy developments (Page 16, 11).
→No detailed disclosures on capacity plans for GLP-1 drugs or innovative molecules yet (Page 16).

How does Sun Pharmaceutical Industries Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sun Pharmaceutical Industries Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sun Pharmaceutical Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio